High Cancer Inflammation Prognostic Index Identifies Patients With Stage II Colorectal Cancer With Outcomes Comparable to Stage III.
Risk stratification after curative resection remains challenging in stage II-III colorectal cancer (CRC). The cancer inflammation prognostic index (CIPI) has been proposed as a novel prognostic marker; however, whether high-risk stage II disease, as defined by CIPI, has outcomes comparable to those of stage III CRC remains unclear, particularly in patients with normal carbohydrate antigen 19-9 (CA19-9) levels.
We retrospectively analyzed 654 patients with pathological stage II-III CRC and normal preoperative CA19-9 who underwent curative resection between 2008 and 2018. Patients were stratified using a validated CIPI cutoff (56.9). Disease-free (DFS) and overall (OS) survival were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.
A high CIPI was significantly associated with poor DFS and OS (both log-rank p<0.01). In multivariate analysis, CIPI ≥56.9 independently predicted worse DFS (hazard ratio=1.91, 95% confidence interval=1.25-2.91; p<0.01) and OS (hazard ratio=2.57, 95% confidence interval=1.42-4.64; p<0.01). Among patients with stage II disease, those with a high CIPI demonstrated DFS and OS comparable to those with stage III CRC (DFS: p=0.31; OS: p=0.49).
CIPI identifies biologically high-risk stage II CRC with long-term outcomes comparable to stage III disease among patients with normal CA19-9 levels, supporting its role as a complementary prognostic tool beyond conventional pathological staging.
We retrospectively analyzed 654 patients with pathological stage II-III CRC and normal preoperative CA19-9 who underwent curative resection between 2008 and 2018. Patients were stratified using a validated CIPI cutoff (56.9). Disease-free (DFS) and overall (OS) survival were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.
A high CIPI was significantly associated with poor DFS and OS (both log-rank p<0.01). In multivariate analysis, CIPI ≥56.9 independently predicted worse DFS (hazard ratio=1.91, 95% confidence interval=1.25-2.91; p<0.01) and OS (hazard ratio=2.57, 95% confidence interval=1.42-4.64; p<0.01). Among patients with stage II disease, those with a high CIPI demonstrated DFS and OS comparable to those with stage III CRC (DFS: p=0.31; OS: p=0.49).
CIPI identifies biologically high-risk stage II CRC with long-term outcomes comparable to stage III disease among patients with normal CA19-9 levels, supporting its role as a complementary prognostic tool beyond conventional pathological staging.
Authors
Kamada Kamada, Takano Takano, Goto Goto, Tsukihara Tsukihara, Kobayashi Kobayashi, Imaizumi Imaizumi, Ryu Ryu, Takeda Takeda, Ohkuma Ohkuma, Kosuge Kosuge, Eto Eto
View on Pubmed